Pharsight

1. List of Kuvan drug patents

Application	Filing Date	Opposition Party	Legal Status
EP18205446A	2022-11-09	Dipharma S.A.	Granted and Under Opposition
EP18205446A	2022-11-09	Coripharma ehf.	Granted and Under Opposition
EP18205446A	2022-10-28	betapharm Arzneimittel GmbH	Granted and Under Opposition
EP16178739A	2022-10-26	Dipharma S.A.	Granted and Under Opposition
EP18205446A	2022-10-12	SANDOZ AG	Granted and Under Opposition
EP16178739A	2022-10-12	TOBIO NOVELFARMA ILAC SAN. VE TIC. A.S.	Granted and Under Opposition
EP16178739A	2022-10-06	STADA Arzneimittel AG	Granted and Under Opposition
EP18205446A	2022-10-05	STADA Arzneimittel AG	Granted and Under Opposition
EP12005352A	2021-09-16	Coripharma ehf.	Granted and Under Opposition
EP12005352A	2021-09-15	betapharm Arzneimittel GmbH	Granted and Under Opposition
EP12005352A	2021-09-14	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP12005352A	2021-09-14	STADA Arzneimittel AG	Granted and Under Opposition
EP12005352A	2021-07-13	Dipharma S.A.	Granted and Under Opposition
EP04820966A	2020-03-11	Lederer & Keller Patentanwälte Partnerschaft mbB	Opposition rejected
EP04819152A	2017-04-20	Alfred E. Tiefenbacher (GmbH & Co. KG)	Revoked
EP04819152A	2017-04-20	DIPHARMA S.A.	Revoked
EP04819152A	2017-04-20	Teva Pharmaceutical Industries Ltd	Revoked
EP08745614A	2013-07-17	Generics [UK] Limited	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612073	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring	Nov, 2024 (1 year, 5 months from now)
US8067416	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 5 months from now)
USRE43797	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin	Nov, 2024 (1 year, 5 months from now)
US7566714	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 5 months from now)
US9433624	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 5 months from now)
US7727987	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (1 year, 5 months from now)
US8318745	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (1 year, 5 months from now)
US9433624 (Pediatric)	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	May, 2025 (1 year, 11 months from now)
US7612073 (Pediatric)	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring	May, 2025 (1 year, 11 months from now)
USRE43797 (Pediatric)	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin	May, 2025 (1 year, 11 months from now)
US8067416 (Pediatric)	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	May, 2025 (1 year, 11 months from now)
US7566714 (Pediatric)	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	May, 2025 (1 year, 11 months from now)
US8318745 (Pediatric)	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	May, 2025 (1 year, 11 months from now)
US7727987 (Pediatric)	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	May, 2025 (1 year, 11 months from now)
US7566462	BIOMARIN PHARM	Stable tablet formulation	Nov, 2025 (2 years from now)
US8003126	BIOMARIN PHARM	Stable tablet formulation	Nov, 2025 (2 years from now)
US7566462 (Pediatric)	BIOMARIN PHARM	Stable tablet formulation	May, 2026 (2 years from now)
US8003126 (Pediatric)	BIOMARIN PHARM	Stable tablet formulation	May, 2026 (2 years from now)
US9216178	BIOMARIN PHARM	Dry blend formulation of tetrahydrobiopterin	Nov, 2032 (9 years from now)
US9216178 (Pediatric)	BIOMARIN PHARM	Dry blend formulation of tetrahydrobiopterin	May, 2033 (9 years from now)

Do you want to check out KUVAN patents from before 2022?

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2007

Treatment: To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Metho...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg	05 Jun, 2014	1	10 May, 2019	16 Nov, 2025	Eligible
100 mg per packet	09 Nov, 2015	1	20 Aug, 2019	17 May, 2025	Eligible Deferred
500 mg per packet	23 Feb, 2017	1	20 Aug, 2019	01 Nov, 2032	Eligible

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

KUVAN family patents

United States

European Union

Japan

Canada

Korea, Republic of

Spain

Australia

Denmark

Portugal

Poland

China

Slovenia

Mexico

Brazil

Hungary

Israel

Croatia

Russia

Hong Kong

Cyprus

Lithuania

Peru

Malaysia

Germany

Argentina

Taiwan

2. List of Voxzogo drug patents

Application	Filing Date	Opposition Party	Legal Status
EP16192229A	2022-09-01	Ascendis Pharma Growth Disorders A/S	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8198242	BIOMARIN PHARM	Variants of C-type natriuretic peptide	Jun, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48267	BIOMARIN PHARM	Variants of C-type natriuretic peptide	May, 2030 (6 years from now)
US9907834	BIOMARIN PHARM	Use of C-type natriuretic peptide variants to treat skeletal dysplasia	Aug, 2036 (13 years from now)
US10646550	BIOMARIN PHARM	Use of C-type natriuretic peptide variants to treat skeletal dysplasia	Aug, 2036 (13 years from now)